0 Evaluaciones
ID

39085

Descripción

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01499303

Link

https://clinicaltrials.gov/show/NCT01499303

Palabras clave

Versiones (1)
  1. 29/11/19 29/11/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

29 de noviembre de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

    Sin comentarios

    Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

    Eligibility Diffuse Large B-Cell Lymphoma NCT01499303

    Inglés

    Eligibility Diffuse Large B-Cell Lymphoma NCT01499303

    1 formularios  
    Inclusion Criteria
    Descripción

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    aged at least 18 years of age.
    Descripción

    Age

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    patients with relapsed or refractory diffuse large b-cell lymphoma who have previously received r-chop (or equivalent) chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue.
    Descripción

    Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory | R-CHOP Regimen | Equivalent | High-Dose Chemotherapy with Autologous Stem Cell Transplant | Patients Ineligible High-Dose Chemotherapy with Autologous Stem Cell Transplant

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0855111
    UMLS CUI [2]
    C0855112
    UMLS CUI [3]
    C0393023
    UMLS CUI [4]
    C0205163
    UMLS CUI [5]
    C1512429
    UMLS CUI [6,1]
    C0030705
    UMLS CUI [6,2]
    C1512714
    UMLS CUI [6,3]
    C1512429
    measurable disease as defined by cheson et al 2007 criteria.
    Descripción

    Measurable Disease

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C1513041
    one fresh pre-treatment excisional or core needle biopsy from suitable and accessible site.
    Descripción

    Pre treatment Excision biopsy Site Suitable | Pre treatment Core needle biopsy Site Suitable

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1,1]
    C2709094
    UMLS CUI [1,2]
    C0184921
    UMLS CUI [1,3]
    C1515974
    UMLS CUI [1,4]
    C3900053
    UMLS CUI [2,1]
    C2709094
    UMLS CUI [2,2]
    C1318309
    UMLS CUI [2,3]
    C1515974
    UMLS CUI [2,4]
    C3900053
    world health organization (who) performance status 0 to 1.
    Descripción

    WHO performance status scale

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C1298650
    Exclusion Criteria
    Descripción

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    treatment with nitrosurea, mitomycin c, investigational agents or study drugs w/in28 days of first dose of study treatment, any other chemotherapy, immunotherapy or anticancer agents w/in 3 weeks of first dose of study treatment, previous fostamatinib.
    Descripción

    Nitrosourea | Mitomycin | Investigational New Drugs | Chemotherapy | Immunotherapy | Antineoplastic Agents | fostamatinib

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0028210
    UMLS CUI [2]
    C0002475
    UMLS CUI [3]
    C0013230
    UMLS CUI [4]
    C0392920
    UMLS CUI [5]
    C0021083
    UMLS CUI [6]
    C0003392
    UMLS CUI [7]
    C2713632
    with the exception of alopecia, any unresolved toxicities from prior therapy or surgery greater than common terminology criteria for adverse events (ctcae) grade 1.
    Descripción

    Exception Alopecia | Prior Therapy Resulting in Toxicity CTCAE Grades | Operative Surgical Procedures Resulting in Toxicity CTCAE Grades | Resolution Lacking

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1,1]
    C1705847
    UMLS CUI [1,2]
    C0002170
    UMLS CUI [2,1]
    C1514463
    UMLS CUI [2,2]
    C0332294
    UMLS CUI [2,3]
    C0600688
    UMLS CUI [2,4]
    C1516728
    UMLS CUI [3,1]
    C0543467
    UMLS CUI [3,2]
    C0332294
    UMLS CUI [3,3]
    C0600688
    UMLS CUI [3,4]
    C1516728
    UMLS CUI [4,1]
    C1514893
    UMLS CUI [4,2]
    C0332268
    uncontrolled hypertension (defined as >140mmhg systolic and/or > 90 mmhg diastolic at baseline with or without antihypertensive therapy.
    Descripción

    Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure | Antihypertensive therapy | Antihypertensive therapy Absent

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C1868885
    UMLS CUI [2]
    C0871470
    UMLS CUI [3]
    C0428883
    UMLS CUI [4]
    C0585941
    UMLS CUI [5,1]
    C0585941
    UMLS CUI [5,2]
    C0332197
    evidence of tuberculosis (tb).
    Descripción

    Tuberculosis

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0041296
    inadequate boen marrow reserve.
    Descripción

    Few mature neutrophils in the bone marrow

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C2748959
    Volver a la parte superior de la página

    Similar models

    Eligibility Diffuse Large B-Cell Lymphoma NCT01499303

    1 formularios
    Name
    Tipo
    Description | Question | Decode (Coded Value)
    Tipo de datos
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Age
    Item
    aged at least 18 years of age.
    boolean
    C0001779 (UMLS CUI [1])
    Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory | R-CHOP Regimen | Equivalent | High-Dose Chemotherapy with Autologous Stem Cell Transplant | Patients Ineligible High-Dose Chemotherapy with Autologous Stem Cell Transplant
    Item
    patients with relapsed or refractory diffuse large b-cell lymphoma who have previously received r-chop (or equivalent) chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue.
    boolean
    C0855111 (UMLS CUI [1])
    C0855112 (UMLS CUI [2])
    C0393023 (UMLS CUI [3])
    C0205163 (UMLS CUI [4])
    C1512429 (UMLS CUI [5])
    C0030705 (UMLS CUI [6,1])
    C1512714 (UMLS CUI [6,2])
    C1512429 (UMLS CUI [6,3])
    Measurable Disease
    Item
    measurable disease as defined by cheson et al 2007 criteria.
    boolean
    C1513041 (UMLS CUI [1])
    Pre treatment Excision biopsy Site Suitable | Pre treatment Core needle biopsy Site Suitable
    Item
    one fresh pre-treatment excisional or core needle biopsy from suitable and accessible site.
    boolean
    C2709094 (UMLS CUI [1,1])
    C0184921 (UMLS CUI [1,2])
    C1515974 (UMLS CUI [1,3])
    C3900053 (UMLS CUI [1,4])
    C2709094 (UMLS CUI [2,1])
    C1318309 (UMLS CUI [2,2])
    C1515974 (UMLS CUI [2,3])
    C3900053 (UMLS CUI [2,4])
    WHO performance status scale
    Item
    world health organization (who) performance status 0 to 1.
    boolean
    C1298650 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    Nitrosourea | Mitomycin | Investigational New Drugs | Chemotherapy | Immunotherapy | Antineoplastic Agents | fostamatinib
    Item
    treatment with nitrosurea, mitomycin c, investigational agents or study drugs w/in28 days of first dose of study treatment, any other chemotherapy, immunotherapy or anticancer agents w/in 3 weeks of first dose of study treatment, previous fostamatinib.
    boolean
    C0028210 (UMLS CUI [1])
    C0002475 (UMLS CUI [2])
    C0013230 (UMLS CUI [3])
    C0392920 (UMLS CUI [4])
    C0021083 (UMLS CUI [5])
    C0003392 (UMLS CUI [6])
    C2713632 (UMLS CUI [7])
    Exception Alopecia | Prior Therapy Resulting in Toxicity CTCAE Grades | Operative Surgical Procedures Resulting in Toxicity CTCAE Grades | Resolution Lacking
    Item
    with the exception of alopecia, any unresolved toxicities from prior therapy or surgery greater than common terminology criteria for adverse events (ctcae) grade 1.
    boolean
    C1705847 (UMLS CUI [1,1])
    C0002170 (UMLS CUI [1,2])
    C1514463 (UMLS CUI [2,1])
    C0332294 (UMLS CUI [2,2])
    C0600688 (UMLS CUI [2,3])
    C1516728 (UMLS CUI [2,4])
    C0543467 (UMLS CUI [3,1])
    C0332294 (UMLS CUI [3,2])
    C0600688 (UMLS CUI [3,3])
    C1516728 (UMLS CUI [3,4])
    C1514893 (UMLS CUI [4,1])
    C0332268 (UMLS CUI [4,2])
    Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure | Antihypertensive therapy | Antihypertensive therapy Absent
    Item
    uncontrolled hypertension (defined as >140mmhg systolic and/or > 90 mmhg diastolic at baseline with or without antihypertensive therapy.
    boolean
    C1868885 (UMLS CUI [1])
    C0871470 (UMLS CUI [2])
    C0428883 (UMLS CUI [3])
    C0585941 (UMLS CUI [4])
    C0585941 (UMLS CUI [5,1])
    C0332197 (UMLS CUI [5,2])
    Tuberculosis
    Item
    evidence of tuberculosis (tb).
    boolean
    C0041296 (UMLS CUI [1])
    Few mature neutrophils in the bone marrow
    Item
    inadequate boen marrow reserve.
    boolean
    C2748959 (UMLS CUI [1])
    Volver a la parte superior de la página 

    Ayuda

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial